Maiko Tanaka

Fujisawa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

In vitro and in vivo rescue of dopaminergic neurons in Parkinson's disease models after Parkin gene therapy.

In vitro and in vivo rescue of dopaminergic neurons in Parkinson's disease models after Parkin gene therapy.

Journal: Gene therapy

Published: June 12, 2025

Compound 4f, a novel brain-penetrant reversible monoacylglycerol inhibitor, ameliorates neuroinflammation, neuronal cell loss, and cognitive impairment in mice with kainic acid-induced neurodegeneration.

Compound 4f, a novel brain-penetrant reversible monoacylglycerol inhibitor, ameliorates neuroinflammation, neuronal cell loss, and cognitive impairment in mice with kainic acid-induced neurodegeneration.

Journal: PloS one

Published: June 07, 2024

AAV delivery of GBA1 suppresses α-synuclein accumulation in Parkinson's disease models and restores functions in Gaucher's disease models.

AAV delivery of GBA1 suppresses α-synuclein accumulation in Parkinson's disease models and restores functions in Gaucher's disease models.

Journal: PloS one

Published: April 26, 2024

Phosphorylation of α-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson's disease.

Phosphorylation of α-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson's disease.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: May 30, 2023

Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.

Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.

Journal: SLAS discovery : advancing life sciences R & D

Published: March 28, 2023

A new brain-penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease.

A new brain-penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease.

Journal: Journal of neurochemistry

Published: April 14, 2021

A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.

A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.

Journal: Scientific reports

Published: April 13, 2021

Preclinical characterization of AMPA receptor potentiator TAK-137 as a therapeutic drug for schizophrenia.

Preclinical characterization of AMPA receptor potentiator TAK-137 as a therapeutic drug for schizophrenia.

Journal: Pharmacology research & perspectives

Published: February 15, 2019

In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M1 Receptor, and Xanomeline, an Agonist of Muscarinic M1/M4 Receptor, in Rodents.

In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M1 Receptor, and Xanomeline, an Agonist of Muscarinic M1/M4 Receptor, in Rodents.

Journal: Neuroscience

Published: December 25, 2018

TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects.

TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects.

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Published: April 04, 2018

TAK-137, an AMPA-R potentiator with little agonistic effect, has a wide therapeutic window.

TAK-137, an AMPA-R potentiator with little agonistic effect, has a wide therapeutic window.

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Published: April 02, 2018

Characterization of CRF1 receptor antagonists with differential peripheral vs central actions in CRF challenge in rats.

Characterization of CRF1 receptor antagonists with differential peripheral vs central actions in CRF challenge in rats.

Journal: Peptides

Published: October 28, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026